Disclosure statement
Jan Philipp Bewersdorf: no conflict of interests. Richard Stone: Abbvie: advisory board; Actinium: advisory board; Arog: advisory board; BMS: advisory board; Boston Pharmaceuticals: advisory board; GSK: AML expert council; Janssen: advisory board; Jazz: advisory board; Novartis: advisory board; Syros: advisory board; Takeda: advisory board, data and safety monitoring board. Martin S. Tallman: Abbvie: research funding; Cellerant: research funding; Orsenix: research funding; ADC Therapeutics: research funding; BioSight: Membership on an entity's Board of Directors or advisory committees and research funding; Glycomimetics: research funding; Rafael: research funding; Amgen: research funding; Bioline rx: Membership on an entity's Board of Directors or advisory committees. Daiichi-Sankyo: Membership on an entity's Board of Directors or advisory committees; KAHR: Membership on an entity's Board of Directors or advisory committees; Rigel: Membership on an entity's Board of Directors or advisory committees; Delta Fly Pharma: Membership on an entity's Board of Directors or advisory committees; Oncolyze: Membership on an entity's Board of Directors or advisory committees; Jazz Pharma: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; UpToDate: Patents & Royalties; Innate Pharmaceuticals: Advisory Board; Kura Oncology: Advisory Board. Maximilian Stahl: No conflict of interests.